Postoperative radiation therapy for patients who have resected non-small cell lung cancer

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The role of adjuvant postoperative therapy for patients who have resected non-small cell lung cancer (NSCLC) has been controversial. Recent large trials and meta-analysis support a modest, but significant, survival benefit for postoperative adjuvant chemotherapy. Postoperative radiation therapy has little potential benefit in patients who have N0 or N1 disease and should not be used routinely in these patients. There are suggestions of benefit for patients who have N2 disease, but adequately powered trials have not been conducted to demonstrate a possible small, but clinically worthwhile, survival benefit in this subgroup. Central nervous system relapse has emerged as an increasing problem for patients who have NSCLC; trials of prophylactic cranial irradiation are underway in several cooperative trial groups.

Original languageEnglish (US)
Pages (from-to)283-302
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume19
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Cranial Irradiation
Survival
Adjuvant Chemotherapy
Meta-Analysis
Central Nervous System
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{1c53242542944e4e9d15881bf60e6b36,
title = "Postoperative radiation therapy for patients who have resected non-small cell lung cancer",
abstract = "The role of adjuvant postoperative therapy for patients who have resected non-small cell lung cancer (NSCLC) has been controversial. Recent large trials and meta-analysis support a modest, but significant, survival benefit for postoperative adjuvant chemotherapy. Postoperative radiation therapy has little potential benefit in patients who have N0 or N1 disease and should not be used routinely in these patients. There are suggestions of benefit for patients who have N2 disease, but adequately powered trials have not been conducted to demonstrate a possible small, but clinically worthwhile, survival benefit in this subgroup. Central nervous system relapse has emerged as an increasing problem for patients who have NSCLC; trials of prophylactic cranial irradiation are underway in several cooperative trial groups.",
author = "Henry Wagner",
year = "2005",
month = "4",
doi = "10.1016/j.hoc.2005.02.006",
language = "English (US)",
volume = "19",
pages = "283--302",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Postoperative radiation therapy for patients who have resected non-small cell lung cancer. / Wagner, Henry.

In: Hematology/Oncology Clinics of North America, Vol. 19, No. 2, 04.2005, p. 283-302.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Postoperative radiation therapy for patients who have resected non-small cell lung cancer

AU - Wagner, Henry

PY - 2005/4

Y1 - 2005/4

N2 - The role of adjuvant postoperative therapy for patients who have resected non-small cell lung cancer (NSCLC) has been controversial. Recent large trials and meta-analysis support a modest, but significant, survival benefit for postoperative adjuvant chemotherapy. Postoperative radiation therapy has little potential benefit in patients who have N0 or N1 disease and should not be used routinely in these patients. There are suggestions of benefit for patients who have N2 disease, but adequately powered trials have not been conducted to demonstrate a possible small, but clinically worthwhile, survival benefit in this subgroup. Central nervous system relapse has emerged as an increasing problem for patients who have NSCLC; trials of prophylactic cranial irradiation are underway in several cooperative trial groups.

AB - The role of adjuvant postoperative therapy for patients who have resected non-small cell lung cancer (NSCLC) has been controversial. Recent large trials and meta-analysis support a modest, but significant, survival benefit for postoperative adjuvant chemotherapy. Postoperative radiation therapy has little potential benefit in patients who have N0 or N1 disease and should not be used routinely in these patients. There are suggestions of benefit for patients who have N2 disease, but adequately powered trials have not been conducted to demonstrate a possible small, but clinically worthwhile, survival benefit in this subgroup. Central nervous system relapse has emerged as an increasing problem for patients who have NSCLC; trials of prophylactic cranial irradiation are underway in several cooperative trial groups.

UR - http://www.scopus.com/inward/record.url?scp=17044382570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044382570&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2005.02.006

DO - 10.1016/j.hoc.2005.02.006

M3 - Review article

C2 - 15833407

AN - SCOPUS:17044382570

VL - 19

SP - 283

EP - 302

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -